Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that women with polycystic ovary syndrome have more pronounced metabolic alterations and higher androgen levels compared to women with eumenorrheic hyperandrogenism, suggesting EuHyperA may be a milder form of PCOS.

In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.

This study found that metformin therapy is associated with the initiation of ovulatory cycles in women with PCOS and a trend toward reduced 17P responses after six months, but did not improve hirsutism or body composition.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

This study found that treatment with the GnRH agonist Triptorelin significantly decreased invasion and expression of S100A4 and CYR61 in certain breast cancer cells, suggesting a potential role in slowing cancer progression.

This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.

In this study of a postmenopausal woman with hyperandrogenism, GnRH agonist treatment significantly reduced testosterone levels, suggesting the androgen excess was ovarian in origin and indicating the potential of using GnRH agonists as a conservative treatment option when surgery is not feasible.

This study found that long-term GnRH agonist administration in premenopausal women with polycystic ovarian disease resulted in persistent suppression of ovarian steroid secretion, while adrenal steroid levels remained unchanged.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

This study found that nafarelin treatment significantly reduced androgen levels and improved hirsutism symptoms in women, suggesting it may be useful for managing this condition.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

This study found that low doses of leuprolide effectively suppressed serum estradiol and LH response, while higher doses were needed to suppress testosterone and reduce hair growth in hirsute women.

This study found that the LH response to nafarelin effectively distinguished gonadotropin deficiency from constitutional delay of puberty, performing comparably to the sleep test and offering certain advantages.

This study found that GnRH agonist treatment improved hirsutism scores more than finasteride after six months in women with idiopathic hirsutism, with both treatments causing no menstrual abnormalities or side-effects.

This study found that treatment with a GnRH agonist and estrogen and progestin replacement significantly improved hirsutism scores and hair growth rates in women with polycystic ovarian disease.

This study describes a postmenopausal woman's diagnosis with ovarian hyperthecosis, confirmed by a GnRHa test normalizing testosterone, highlighting hormone therapy as a therapeutic option when surgery is not feasible.

This updated guideline from the Endocrine Society highlights the importance of endocrinologists in providing safe and effective hormone regimens for gender-affirming care, especially for adolescents who have entered puberty.

This review explores the mechanisms of intratesticular control of steroidogenesis and indicates the need for further controlled studies; it presents no new experimental findings.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

This article reviews the hormonal pathogenesis and treatment strategies for acne vulgaris, particularly in women with severe or treatment-resistant cases, associating it with hormonal imbalances and hyperandrogenism.

This review discusses cardiovascular risks associated with androgen deprivation therapy in prostate cancer patients and highlights ongoing research, including the potential reduced COVID-19 susceptibility, but reports no new results.

This article discusses various hormonal therapies for acne and provides practical treatment guidelines for managing hormonally related acne, but it reports no new research findings.

This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.

This review discusses various anti-androgen treatments for hirsutism, including androgen receptor blockers and inhibitors, and emphasizes the role of diagnosis in selecting the most appropriate therapy, but reports no new clinical results.

This article discusses various diagnostic categories and treatments for hyperandrogenism, with a focus on polycystic ovary syndrome and reports no new clinical findings, calling for specific treatments and lifestyle changes.

This review discusses symptom-driven treatment approaches for PCOS, focusing on ovulation induction, androgen reduction, and weight management, and reports recent advances like recombinant FSH and GnRH-agonist protocols without providing new clinical results.

This review summarizes existing clinical guidelines for hormonal therapy in gender dysphoria, observing similarities in international practices and emphasizing the need for more evidence-based research, particularly on GnRH agonists for both trans women and men.

This review summarizes the structural and chemical characteristics of current and novel antiandrogenic drugs but reports no new clinical findings.

This article reviews the causes and treatments of hypertrichosis and hirsutism and reports no new clinical findings; the authors compare diagnostic strategies and discuss available treatment options.